Kennedy Capital Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
KCM
BBA
Kennedy Capital Management's CLDX Position: Q3 2026 in Review
Kennedy Capital Management increased its Celldex Therapeutics (CLDX) stake by 5.6% in Q3 2026, buying an estimated $735K and bringing the position to 361,556 shares worth $11.7M. The position accounts for 0.22% of the portfolio, ranked #158.
Kennedy Capital Management first reported a position in CLDX in Q4 2021 and has held it in 13 quarters since. The position peaked at $12.7M in Q2 2026. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Kennedy Capital Management held 361,556 shares of Celldex Therapeutics worth $11.7M as of Q3 2026.
- Kennedy Capital Management bought 19,228 Celldex Therapeutics shares in Q3 2026, an estimated $735K.
- Celldex Therapeutics made up 0.22% of Kennedy Capital Management's portfolio in Q3 2026, its #158 holding.
- Kennedy Capital Management first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 13 quarters since.
- Kennedy Capital Management's Celldex Therapeutics position peaked at $12.7M in Q2 2026.
- 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.